Ilumetri
tildrakizumab
Table of contents
Overview
Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable.
Ilumetri contains the active substance tildrakizumab.
-
List item
Ilumetri : EPAR - Medicine overview (PDF/74.73 KB)
First published: 09/10/2018
EMA/621733/2018 -
-
List item
Ilumetri : EPAR - Risk-management-plan summary (PDF/77.53 KB)
First published: 09/10/2018
Authorisation details
Product details | |
---|---|
Name |
Ilumetri
|
Agency product number |
EMEA/H/C/004514
|
Active substance |
tildrakizumab
|
International non-proprietary name (INN) or common name |
tildrakizumab
|
Therapeutic area (MeSH) |
Psoriasis
|
Anatomical therapeutic chemical (ATC) code |
L04AC
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Almirall S.A
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
17/09/2018
|
Contact address |
Ronda General Mitre
151 08022 Barcelona Spain |
Product information
26/01/2023 Ilumetri - EMEA/H/C/004514 - II/0036
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunosuppressants
-
Interleukin inhibitors
Therapeutic indication
Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.